68Ga-NODAGA-SNA006 PET/CT显像评估肿瘤CD8+ T细胞浸润预测肺癌免疫治疗反应
前瞻性研究纳入8例接受一线化疗联合抗PD-1/PD-L1免疫治疗的肺癌患者,治疗前行68Ga-SNA006 PET/CT显像。SUVmax与间质CD8+ T细胞浸润显著相关(R²=0.8218,P=0.0338),TBR对治疗反应预测的AUC为0.87。
要点
- SUVmax与间质CD8+ T细胞浸润显著相关(R²=0.8218,P=0.0338),与瘤内浸润无显著相关。
- 24个病灶分析中TBR与病灶缩小相关性最强(R²=0.3178,P<0.01)。
- TBR预测治疗反应的AUC为0.87,截断值TBR>2.120时敏感度62.5%、特异度93.3%。
核心结论
- 68Ga-NODAGA-SNA006 PET/CT为肺癌患者免疫细胞浸润和治疗反应提供有价值的信息。
- 研究凸显TBR作为预后生物标志物的潜力,并强调将多参数影像整合到临床决策中的重要性。
研究设计与样本
- 前瞻性研究纳入8例组织学确诊的肺癌患者,接受一线化疗联合抗PD-1/PD-L1免疫治疗。
- 治疗前行68Ga-SNA006 PET/CT显像,分析肿瘤SUVmax与CD8+ T细胞浸润的相关性及多参数影像指标与治疗结局的关联。
主要发现
- SUVmax与间质CD8+ T细胞浸润显著相关(R²=0.8218,P=0.0338),与瘤内浸润无显著相关(R²=0.5178,P>0.05)。
- 8例患者中6例达部分缓解、2例达疾病稳定(2个治疗周期后)。
- 基线血CD8+ T细胞、Ki67%和PD-L1%无预后意义,SUVmax与治疗后病灶缩小无相关。
- 24个病灶分析中,TBR与病灶缩小的相关性最强(R²=0.3178,P<0.01)。
关键数值与推荐
- ROC分析显示TBR预测治疗反应的诊断效能最高(AUC=0.87)。
- 截断值TBR>2.120时敏感度62.5%、特异度93.3%;TBR>5.535时敏感度87.5%、特异度66.7%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study aimed to evaluate the potential of 68 Ga-NODAGA-SNA006 PET/CT imaging as a noninvasive method for assessing immune cell infiltration and predicting treatment response in lung cancer patients undergoing immunotherapy. PATIENTS AND METHODS: A prospective study enrolled 8 patients with histologically confirmed lung cancer who received first-line chemotherapy combined with anti-PD-1/PD-L1 immunotherapy. 68 Ga-SNA006 PET/CT imaging was performed before treatment. The primary endpoints analyzed the correlation between tumor SUVmax and CD8 + T-cell infiltration, as well as associations of multiparametric imaging parameters (SUVmax, TBR, TLR, TSR, and TMR) with treatment outcomes. RESULTS: The SUVmax significantly correlated with stromal CD8 + T-cell infiltration (R 2 = 0.8218, P = 0.0338) but not with intratumoral infiltration (R 2 = 0.5178, P > 0.05), indicating its stromal-specific association with immune activity. Among 8 patients, 6 achieved partial response and 2 stable diseases after 2 treatment cycles. Baseline blood CD8 + T cells, Ki67%, and PD-L1% showed no prognostic significance, nor did SUVmax correlate with posttreatment lesion reduction. In 24 lesions analyzed, TBR demonstrated the strongest correlation with lesion reduction (R 2 = 0.3178, P < 0.01). ROC analysis further revealed that TBR had the highest diagnostic efficacy (AUC = 0.87) for predicting treatment response, with a sensitivity of 62.5% and specificity of 93.3% at a cutoff value of TBR >2.120, and a sensitivity of 87.5% and specificity of 66.7% at TBR >5.535. CONCLUSIONS: 68 Ga-NODAGA-SNA006 PET/CT provides valuable insights into immune cell infiltration and treatment response in lung cancer patients. The study highlights the potential of TBR as a prognostic biomarker and underscores the importance of integrating multiparametric imaging into clinical decision-making.
引用
- Zhou J, Zhou M, Chen W, et al. 68 Ga-NODAGA-SNA006 PET/CT Imaging of Tumor CD8 + T-Cell Infiltration Predicts Immunotherapy Response in Lung Cancer. Clin Nucl Med. 2025. PMID: 40902989. doi:10.1097/RLU.0000000000006098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。